Peitel

Quick links to important sections

Peitel

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Peitel

Quick Facts

Property Description
Active Ingredient Prednicarbate
Form Cream, Ointment (Semisolid)
Pharmacological Class Topical Corticosteroid (Glucocorticoid)
Potency Classification Medium-Potency
Origin Synthetic

What is Peitel? Defining Prednicarbate's Identity and Class

The medicine Peitel is a prescription-only medication whose active component is the single chemical ingredient Prednicarbate. It is classified as a powerful Topical Corticosteroid, belonging to the larger family of Glucocorticoids, and is designed strictly for external use on the skin. This classification is clinically recognized for managing inflammatory skin conditions.

Pharmacologically, Prednicarbate is a unique synthetic and fluorinated steroid compound, which structurally differentiates it from basic hydrocortisone preparations. Within the international classification systems, it is recognized as a Medium-Potency agent. This categorization means Peitel provides a substantial degree of anti-inflammatory and localized immunosuppressive activity, offering effective intervention for persistent dermatological conditions, such as chronic eczema or moderate psoriasis, where milder treatments have proven insufficient.


Origin, Form, and General Purpose

Peitel is formulated exclusively as a semisolid dosage form—either a Cream or an Ointment—to facilitate Topical (Cutaneous) administration. Its general therapeutic purpose is to provide symptomatic relief by powerfully suppressing the processes that cause inflammation and intense itching in the skin.

The choice between the lighter Cream base and the occlusive Ointment base ensures appropriate delivery of the Prednicarbate tailored to the specific characteristics of the skin lesion. By targeting the underlying inflammatory cascade, Peitel’s mechanism provides its fundamental general benefit: soothing irritated tissue and effectively breaking the self-perpetuating cycle of inflammation, redness, and severe pruritus. This consistent action is paramount for managing long-term inflammatory issues.

Regulatory References

  1. Topical Corticosteroids - StatPearls - NCBI Bookshelf

What side effects are possible with Peitel?

Possible Side Effects and Safety Information

The safety profile of Peitel (Prednicarbate), a medium-potency topical corticosteroid, is defined by potential local skin reactions and the risk of systemic effects from absorption, as documented in regulatory prescribing information.


Local Adverse Reactions

The most frequently reported adverse reactions are local effects at the application site. In controlled clinical studies, these effects were documented as common and include sensations such as burning and pruritus (itching), as well as drying, scaling, cracking, and irritant dermatitis. Other documented dermatological effects include skin atrophy (thinning), striae (stretch marks), folliculitis, and changes in pigmentation.


Systemic Safety Concerns

While uncommon, systemic absorption of the active ingredient may lead to serious adverse reactions related to the Endocrine System. These include reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and the manifestations of Cushing's syndrome. The risk of such effects is associated with prolonged use, application over large surface areas, and use under occlusive dressings. Intracranial hypertension has also been specifically documented in pediatric patients.


Population-Specific Safety

Pediatric patients are officially noted to have greater susceptibility to systemic toxicity, including HPA axis suppression and related effects, due to their higher skin surface area to body weight ratio. The use of the medicine is generally contraindicated in individuals with a known history of hypersensitivity to any component of the formulation. Furthermore, ingredients in the medicine’s base may compromise the integrity of latex-containing products.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Peitel (Prednicarbate) is defined by the potential for systemic effects resulting from sufficient percutaneous absorption of the topical corticosteroid. This risk is primarily associated with applying the product to a large surface area, using it for prolonged periods, or utilizing occlusive dressings.

Documented Manifestations and Consequences

Official regulatory documents state that systemic absorption can lead to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, along with manifestations of Cushing's syndrome, hyperglycemia, and glucosuria.

The severe outcome identified is the potential for glucocorticosteroid insufficiency following the withdrawal of the treatment after HPA axis suppression has occurred. No specific antidote is documented for this type of overdose, and management is generally symptomatic and supportive.

Mandatory Emergency Actions

Regulators require individuals to seek immediate medical attention for suspected overdose or any observed signs of systemic toxicity. If HPA axis suppression is confirmed through laboratory monitoring, the mandated action is to withdraw the drug, reduce the frequency of application, or substitute a less potent corticosteroid.

Pediatric patients are noted in official labeling as being at a greater risk for systemic toxicity and HPA axis suppression due to their higher skin surface area to body mass ratio.

Therapeutic Uses of Peitel

What Peitel Treats: Main Uses and Benefits

Peitel (Prednicarbate) is commonly used across therapeutic domains where additional symptomatic support is needed for corticosteroid-responsive dermatoses, including eczema, various forms of dermatitis (such as Atopic Dermatitis), and psoriasis. It is commonly applied in clinical settings that involve inflammatory or irritative processes, particularly where patients require supportive management for symptoms that become more disruptive during flare-ups. The medication is considered relevant for easing symptoms that interfere with daily comfort and is used within these therapeutic areas to manage significant symptom expression.


Key Symptom Management

The medication is applied across domains where additional symptomatic support is needed for managing symptom clusters that may become intense, such as pronounced redness (erythema), localized swelling (edema), and the severe itching (pruritus). This approach supports patients during difficult episodes by easing the impact of symptoms on general comfort. It is relevant in clinical settings that involve acute or unstable symptom patterns, such as weeping or oozing lesions, which may interfere with routine activities.

This treatment is considered relevant for both adults and pediatric patients (aged 1 and older) for symptomatic management. It may be part of supportive management in scenarios requiring assistance for widespread lesions or in sensitive skin regions where additional symptomatic support is needed.


QuickFact

Property Description
Symptom Domains Addressed Pronounced redness, swelling, and severe itching (pruritus)
Key Patient Group Adults and pediatric patients (aged 1+) with chronic dermatoses
Typical Context Symptoms that are persistent or become disruptive during flare-ups

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Peitel — Official Regulatory Information

Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Adults and Older Adults.
  • Pediatric patients aged 1 year and older (Cream formulation only).

Populations for whom use is contraindicated:

  • Patients with a history of hypersensitivity to Prednicarbate or any component.
  • Patients with untreated viral, bacterial, fungal, or parasitic skin infections (e.g., chickenpox, skin tuberculosis).

Age-related eligibility rules:

  • The cream formulation is established for children 1 year and older.
  • The ointment formulation's safety and effectiveness have not been established in children below the age of 10 years.

Pregnancy and lactation eligibility status (if explicitly documented):

  • Pregnancy: Classified as Category C. Use is conditional and permitted only if the potential benefit justifies the potential risk to the fetus.
  • Lactation: Caution should be exercised when administering to a nursing woman.

Eligibility-related restrictions:

  • The medicine is not recommended for application on the face, underarms, or groin areas.
  • Use is contraindicated for ophthalmic purposes and for treating acne rosacea or perioral dermatitis.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents):

  • Contraindicated (e.g., hypersensitivity, infection, ophthalmic use).
  • Not Recommended (e.g., use on the face, use for diaper dermatitis).
  • Use Not Established (e.g., ointment in children under 10 years).

Connection to the overall eligibility profile: Regulatory documents establish the framework for Peitel use by defining absolute prohibitions for hypersensitivity and active infections, and by specifying conditional use for pregnancy and lactation. Furthermore, eligibility is structured by age and application site, with specific exclusions for use on the eyes, face, and under occlusive dressings, thereby delineating the boundaries of authorized use.

What should I know about interactions with other medicines?

Peitel (prednicarbate) is a topical corticosteroid, and interactions with other medicines are generally not anticipated when the product is used as directed. Systemic drug-drug interactions, which typically involve one medicine affecting the way the body processes another, are not widely documented for topical corticosteroids when absorption is minimal. However, because this medicine can be absorbed through the skin, caution is appropriate, particularly if other corticosteroids or similar medications are being used.

Documented Product and Substance Interactions

Peitel cream and ointment formulations contain an excipient (such as paraffin or petrolatum) which has a specific physical interaction. This component can cause latex products to break down, leak, or tear, leading to a loss of effectiveness. This includes latex-containing products like condoms and diaphragms.

  • Avoid contact between the cream or ointment and any latex-containing barrier contraceptives. If contact occurs, the latex product should be discarded, as its barrier function may be compromised.

Procedural and Other Considerations

If the treated skin area develops an infection, such as a bacterial or fungal superinfection, the regulatory labels indicate that appropriate additional antibacterial or antifungal therapy must be administered concurrently with Peitel. This is not a drug interaction, but a necessary therapeutic step to manage a complication that may arise during topical steroid use.

Mechanism of Action

How Peitel Works: Pharmacodynamic Mechanism

The action of Prednicarbate is initiated by agonist binding to the intracellular Glucocorticoid Receptor (GR) within target cells. This interaction triggers a genomic process where the ligand-receptor complex modulates gene expression, leading to the synthesis of Lipocortin proteins. These Lipocortins then act to indirectly inhibit the enzyme Phospholipase A2 ( PLA2), thereby halting the release of Arachidonic Acid from the cell membrane. This blockade effectively prevents the biosynthesis of inflammatory mediators, including Prostaglandins and Leukotrienes.

This molecular cascade contributes to the sustained modulation of inflammatory signaling, resulting in the core physiological change of reduced fluid extravasation and dampened nociceptive signaling at the cellular level. Additionally, the mechanism includes a localized action that induces vasoconstriction of dermal blood vessels. This physical adjustment results in the physiological effect of attenuated vascular permeability and reduced capillary dilatation.

Dosage and Administration Information

How to Use Peitel

The administration of Peitel (prednicarbate) is strictly limited to topical (cutaneous) use, as it is formulated solely in semisolid dosage forms, such as cream (0.1% or 0.25%) and ointment (0.1%). Its usage protocol is standardized to maintain consistent application and duration.


Administration Guidelines

Element Official Use Protocol
Administration Route Topical (Cutaneous) use only.
Dosing Schedule Apply a thin film to the affected skin areas.
Frequency Application is typically performed once or twice daily.
Duration of Course Treatment is intended to be short-term, and should be discontinued once control is achieved. Continuous use for more than four weeks is not generally advised.

Specific Procedural Constraints

To ensure proper use, the product must be rubbed in gently after a thin layer is applied. A crucial condition of use is that the treated area must not be bandaged, covered, or wrapped (occluded), unless a physician specifically directs otherwise. General usage standards advise avoiding application to the face, underarms, or groin.

Age-Group Administration Rules: The 0.1% cream formulation may be used in pediatric patients aged one year or older. However, the safety and efficacy of continuous use extending beyond three weeks have not been established in this patient group. The 0.1% ointment formulation is typically reserved for pediatric patients aged 10 years and older.

Connection to the overall use protocol: These explicit instructions define the necessary application technique (thin film), frequency, and strict limitations on duration and occlusion. This protocol ensures that the usage of this medium-potency topical corticosteroid is consistent with a standardized approach.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Peitel

The research evidence for Peitel (Prednicarbate) is centered on its classification as a medium-potency topical corticosteroid and the clinical research conducted for inflammatory skin conditions. The clinical evaluation of this medicine is primarily comprised of studies examining how symptoms change over short time periods, with a key focus on conditions that have fluctuating or episodic manifestations. The evidence helps contextualize how patients reported their experience during periods of heightened symptom activity.


Evidence for Use in Atopic Dermatitis (Eczema)

Studies conducted for the use of Prednicarbate in Atopic Dermatitis (Eczema) typically include short-term Randomized Controlled Trials (RCTs) and multicenter, open-label studies. This research explored outcomes related to physical discomfort and conditions involving periods of heightened symptoms. Studies monitored outcomes linked to inflammatory or irritative states, such as pronounced redness (erythema), localized swelling (edema), and severe itching (pruritus), using clinical assessment scales.

Findings describe group patterns related to measured symptom patterns during the specific study period, which included both adults and children. These findings help contextualize how patients reported their experience during the short-term use of the medicine for conditions characterized by fluctuating manifestations.

Evidence for Use in Chronic Eczema and Other Dermatoses

Prednicarbate was evaluated in research exploring short-term symptom changes associated with other steroid-responsive dermatoses, including various forms of chronic eczema. This research examined outcomes linked to inflammatory or irritative states. Studies often utilized controlled comparative trials, exploring endpoints such as the rate of marked clinical change or the resolution of specific signs like scaling and inflammation.

Research describes patterns related to short-term changes in these chronic conditions. Findings indicate soft, non-causal data show patterns related to outcomes related to physical discomfort over defined treatment intervals, typically three to four weeks. The evidence base for these specific chronic conditions often involves comparisons against other active drugs rather than against a non-active vehicle (placebo).


Research in Specific Patient Groups

Research studies for Prednicarbate examined both adults and pediatric patients (children aged 1 year and older) with widespread atopic dermatitis. Studies monitored outcomes related to systemic or functional imbalance, specifically the potential for impact on the hypothalamic-pituitary-adrenal (HPA) axis function—a key measure of potential systemic exposure for topical corticosteroids. The results apply only to the populations studied. Data for certain groups, such as infants under one year of age or pregnant populations, data are still emerging.

Limitations and Duration of Follow-up

Research for Peitel focused primarily on short-term symptom patterns over defined time intervals, with most controlled trials having observation periods of two to four weeks. This means there is limited information for long-term outcomes that exceed this initial treatment window. While short-term outcomes are well characterized in the trials, long-term effects on chronic disease activity or the risk of disease recurrence are evidence is limited by the existing Prednicarbate-specific research.

Key Studies & References Topical Corticosteroids: Potency Classification and General Use in Dermatology (NIH/MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Peitel (FAQ)

Q: How does Peitel cream differ from over-the-counter hydrocortisone creams?

Peitel (Prednicarbate) is classified by regulatory authorities as a medium-potency topical corticosteroid. This potency level is generally greater than most over-the-counter hydrocortisone preparations, which are typically low-potency.

Q: Is Peitel cream ever appropriate for use on the face?

Official product information advises that this medication should not be used on the face, the underarms, or the groin areas. This is based on the risk of skin thinning (atrophy), which the face is noted as being more prone to.

Q: Can other topical products like moisturizers or sunscreens be used alongside Peitel?

General guidance recommends that you check with a doctor before applying any other topical drugs or products, such as sunscreens or moisturizers, to the skin area being treated with Peitel. This is generally advised to ensure appropriate use and to manage overall skin exposure to topicals.

Q: Is Peitel considered safe to use for older adults?

Regulatory documents explicitly state that Peitel cream can be used in the elderly population.

Q: What are the official warnings about using Peitel on the genital or groin area?

Regulatory documents advise against using this medicine on the groin area. These areas are sensitive and are officially noted as being more prone to atrophic changes (skin thinning) than other parts of the body when exposed to topical steroids.

Q: Is there any information about using Peitel cream during pregnancy or while breastfeeding?

For pregnancy, Peitel is classified as Category C, meaning use is conditional. Official documents advise that long continuous treatment on large skin areas should be avoided, particularly in the first trimester. Caution should be exercised when administering the medicine to a nursing woman, as it is not known if it passes into human milk from topical use.

Q: Is it safe to use Peitel if the skin area has broken skin or an open wound?

Official warnings state that the medicine should not be applied to cuts, scrapes, or damaged skin, and should be avoided in open wounds.

Q: Does the use of Peitel require any regular blood tests or monitoring?

For patients applying the topical steroid to large surface areas or using it under non-breathable dressings, periodic evaluation for evidence of HPA-axis suppression may be needed. HPA-axis suppression is a measure of systemic absorption. The prescribing physician will determine if this type of monitoring is required.

Q: What does it mean that Peitel's active ingredient is 'non-halogenated'?

Prednicarbate is described in some literature as a non-halogenated corticosteroid. This is a chemical feature that has been associated in some literature with a reduced potential to cause skin thinning (atrophy) when compared to some other types of topical steroids.

Q: Is Peitel cream effective for fungal infections?

The medicine is not indicated to treat fungal infections, and topical steroids can sometimes worsen them. If a concurrent fungal infection is present or develops, regulatory guidance states that an appropriate antifungal agent should be used at the same time. The official guidance indicates that the topical steroid should be discontinued if the infection does not respond promptly.

Q: What happens if Peitel cream comes into contact with latex?

The excipients (inactive ingredients) in the cream or ointment can cause damage to latex-containing products, such as condoms and diaphragms. This damage can reduce their effectiveness and barrier function, so contact should be carefully avoided.

Q: What happens if Peitel is accidentally applied near the eyes?

The product is not intended for ophthalmic use (use in the eyes). Using topical corticosteroids near the eye should be done with caution because systemic absorption may cause increased intraocular pressure and potentially lead to conditions like glaucoma or cataracts. If contact occurs, the area should be rinsed with water.

Q: What should a patient expect if their symptoms do not improve after a certain period of using Peitel?

Official guidance advises patients to contact their doctor if their condition does not improve within 2 weeks of using the medicine.

Q: Is Peitel a medicine intended for short-term flares or can it be used intermittently?

Peitel is indicated for inflammatory skin disorders that require topical corticosteroid therapy. Regulatory documents note that it is also suitable for conditions where repeated short-term treatment is required, up to the maximum continuous period of four weeks.

Q: Are there official warnings against using Peitel if a patient has a viral skin infection like cold sores?

Yes, Peitel is contraindicated (should not be used) for treating skin manifestations of viral infections of the skin. This includes common conditions like chicken pox and viral diseases such as cold sores (Herpes simplex).

Q: Can Peitel be used for scalp conditions?

Official administration instructions generally permit application of the topical forms to the skin or scalp, depending on the specific formulation.

Q: Does Peitel have any known effects on blood sugar levels?

Systemic absorption of the medicine, though uncommon when used correctly, may cause manifestations such as hyperglycemia (high blood sugar) or glucosuria (sugar in the urine) in some patients. Patients with a history of diabetes are generally described as a population who should use the drug with caution.

Q: Is there a generic version of Peitel's active ingredient available?

Yes, the active ingredient, Prednicarbate, is available in a lower-cost generic form in many regions, in addition to the brand name Peitel.

Q: What specific components in Peitel can cause local skin reactions like contact dermatitis?

The official product label indicates that the medicine contains excipients such as cetyl alcohol and stearyl alcohol, which may cause local skin reactions such as contact dermatitis. It also contains benzyl alcohol, which may cause allergic reactions and mild local irritation.

How should Peitel be stored and disposed of?

How to Store and Dispose of Peitel (Prednicarbate)

The storage and disposal of Peitel must strictly follow regulatory guidance to ensure product stability and safety.

Storage Conditions

Requirement Detail
Temperature Store at controlled room temperature, between 15°C and 30°C (59°F and 86°F).
Protection Keep from freezing and protect from direct light and moisture.
Container Store in a closed container and keep out of the reach of children.

Disposal and Handling

Official instructions require throwing away any unused medicine after its expiration date. Users should ask a healthcare professional for guidance on how to dispose of product that is no longer needed, rather than discarding it in wastewater or routine trash. A specific handling warning states that the medicine can damage latex; therefore, any latex products that have come into contact with Peitel must be properly discarded.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Peitel found in:

A-Z Index: